Travel restrictions bite Bavarian as rabies vaccine sales plunge

At the end of Q1, Bavarian Nordic presented shrinking sales of vaccines Rabipur/Rabavert against rabies and Encepur against TBE.

Photo: Philip Davali/Ekstra Bladet, Philip Davali

Danish biotechnology company Bavarian Nordic's vaccine against rabies has been tripped up by the covid-19 pandemic and resulting travel restrictions, the firm's Vice President Investor Relations & Communications Rolf Sass Sørensen tells Ritzau Finans following the publication of the firm's Q1 report.

In the first quarter, Bavarian Nordic presented retreated sales for the vaccines Rabipur/Rabavert for rabies and Encepur for tick-borne encephalitis (TBE).

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs